Inactivation of Antibiotic Resistance in Clinical Isolates of Pathogenic Enterobacteriaceae

Nemesis Bioscience发明、开发并保护了一系列新型生物治疗剂，这些治疗剂可以灭活对抗生素的耐药性，从而使成熟和安全的抗生素再次发挥作用。恢复抗生素敏感性消除了“超级细菌”的威胁，并确保当前和新开发的抗生素长期保持功效。该公司已经证明，其“Nemesis Symbiotics”可将耐药细菌（AMR）转化为抗生素敏感性细菌，并防止细菌获得AMR，从而有可能在术前甚至入院前保护患者，以降低随后AMR感染的风险。在目前的研究中，该公司将完成实验工作，以验证其技术在从临床感染中分离的致病菌中的有效性，并证明其共生技术可以在治疗和预防抗生素耐药菌感染方面具有实际应用。该公司产品的开发时间将大大缩短，比现有的抗菌剂。迄今为止，该公司已从其创始人、天使投资者、彩虹种子基金（Rainbow Seed Fund）和威尔士金融（Finance Wales）那里筹集了资金。该公司获得了2014年剑桥大学国王学院创业奖。

Nemesis Bioscience has invented, developed and protected a family of novel biological therapeutic agents that inactivate resistance to antibiotics, so allowing well-established and safe antibiotics to be effective again. Resurrecting antibiotic susceptibility eliminates the threat of ‘super bugs’ and ensures current and newly developed antibiotics retain efficacy over the long-term. The company has proven that its “Nemesis Symbiotics” convert antimicrobial resistant (AMR) bacteria to antibiotic sensitivity and also prevent bacteria from acquiring AMR – presenting the possibility of protecting patients pre-operatively, or even pre-admission, to lower the risks of subsequent AMR infection. In the current study the company will complete experimental work to validate its technology in pathogenic bacteria isolated from clinical infections and demonstrate that its Symbiotic technology can have real-world application for the treatment and prevention of infections with antibiotic resistant bacteria. The company’s products will have significantly shorter development times than existing antimicrobials. To date the company has raised funds from its founders, Angel investors, the Rainbow Seed Fund and from Finance Wales. The company won the King’s College, Cambridge Entrepreneurship Award for 2014.